JPH06502429A - 経皮避妊製剤、方法及びデバイス - Google Patents
経皮避妊製剤、方法及びデバイスInfo
- Publication number
- JPH06502429A JPH06502429A JP4500802A JP50080292A JPH06502429A JP H06502429 A JPH06502429 A JP H06502429A JP 4500802 A JP4500802 A JP 4500802A JP 50080292 A JP50080292 A JP 50080292A JP H06502429 A JPH06502429 A JP H06502429A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- estrogen
- permeation enhancer
- drug
- reservoir
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
- Semiconductor Lasers (AREA)
- Vending Machines For Individual Products (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims (13)
- 1.エストロゲンとST−1435とを含む薬物製剤を経皮投与するための組成 物であって、その薬物製剤の避妊有効量と適当な透過促進剤の皮膚透過促進量と を組み合わせて含む組成物。
- 2.エストロゲンとST−1435とを含む薬物製剤の経皮投与方法であって、 (a)妥当なサイズである皮膚面に避妊有効速度で薬物製剤を投与し;(b)同 時に、薬物製剤に対する該面の選過性を実質的に高めるために充分である速度で 皮膚の該面に適当な透過促進剤を投与することを含む方法。
- 3.女性を避妊する方法であって、 (a)妥当なサイズである、女性の皮膚面に避妊有効速度でエストロゲンとST −1435とを含む薬物製剤を投与し;(b)同時に、薬物製剤に対する該面の 透過性を実質的に高めるために充分である速度で皮膚の該面に適当な透過促進剤 を投与することを含む方法。
- 4.エストロゲンとST−1435とを含む薬物製剤を避妊有効速度で経皮投与 するための、妥当なサイズであるデバイスであって、(a)薬物製剤の避妊有効 量と適当な透過促進剤の皮膚透過促進量とを含有するマトリックスを含む溜め; (b)溜めの皮膚遠位面の不透過性バッキング;及び(c)溜めを皮膚とエスト ロゲン−、ST−1435−及び透過促進剤一伝達関係に維持する手段 を含むデバイス。
- 5.女性を避妊するための妥当なサイズであるデバイスであって、(a)エスト ロゲンとST−1435とを含む薬物製剤の避妊有効量と適当な透過促進剤の皮 膚透過促進量とを含有するマトリックスを含む溜め;(b)溜めの皮膚遠位面の 不透過性バッキング;及び(c)溜めを皮膚と、エストロゲン−、ST−143 5−及び透過促進剤一伝達関係に維持する手段 を含むデバイス。
- 6.エストロゲンがエチニルエストラジオールである請求項1、2、3、4又は 5に記載の組成物、方法又はデバイス。
- 7.透過促進剤が、少なくとも51%の総モノエステル含量を有する、脂肪酸の モノグリセリド又はモノグリセリド混合物である請求項1、2、3、4又は5に 記載の組成物、方法又はデバイス。
- 8.透過促進剤がグリセロールモノオレエート、グリセロールモノリルエート、 又はグリセロールモノラウレートである請求項1、2、3、4又は5に記載の組 成物、方法又はデバイス。
- 9.エストロゲンがエチニルエストラジオールであり、透過促進剤がグリセロー ルモノオレエートである請求項1、2、3、4又は5に記載の組成物、方法又は デバイス。
- 10.エストロゲンがエチニルエストラジオールであり、エチニルエストラジオ ールが所定期間にわたって少なくとも10μg/日の速度で皮膚を通して投与さ れる請求項2、3、4又は5に記載の方法又はデバイス。
- 11.ST−1435が所定期間にわたって少なくとも80μg/日の速度で皮 膚を通して投与される請求項2、3、4又は5に記載の方法又はデバイス。
- 12.エストロゲンがエチニルエストラジオールであり、透過促進剤がグリセロ ールモノオレエートであり、マトリックスが約9〜約60%の酢酸ビニルを有す るエチレン−酢酸ビニルコポリマーを含む請求項4又は5に記載のデバイス。
- 13.溜めを皮膚に対して維持するための手段が溜めの皮膚隣後面にイン−ライ ン接着剤層を含む請求項12記載のデバイス。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/605,726 US5122382A (en) | 1990-10-29 | 1990-10-29 | Transdermal contraceptive formulations, methods and devices |
US605,726 | 1990-10-29 | ||
PCT/US1991/007877 WO1992007589A1 (en) | 1990-10-29 | 1991-10-25 | Transdermal contraceptive formulations, methods and devices |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH06502429A true JPH06502429A (ja) | 1994-03-17 |
JP2975684B2 JP2975684B2 (ja) | 1999-11-10 |
Family
ID=24424948
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP4500802A Expired - Lifetime JP2975684B2 (ja) | 1990-10-29 | 1991-10-25 | 経皮避妊製剤、方法及びデバイス |
Country Status (16)
Country | Link |
---|---|
US (1) | US5122382A (ja) |
EP (1) | EP0577602B1 (ja) |
JP (1) | JP2975684B2 (ja) |
AT (1) | ATE171069T1 (ja) |
AU (1) | AU9041991A (ja) |
CA (1) | CA2088778C (ja) |
DE (1) | DE69130232T2 (ja) |
DK (1) | DK0577602T3 (ja) |
ES (1) | ES2123547T3 (ja) |
IE (1) | IE913741A1 (ja) |
MX (1) | MX9101784A (ja) |
NO (1) | NO303527B1 (ja) |
NZ (1) | NZ240361A (ja) |
PT (1) | PT99340B (ja) |
WO (1) | WO1992007589A1 (ja) |
ZA (1) | ZA918531B (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11505843A (ja) * | 1995-05-26 | 1999-05-25 | アルザ コーポレイション | アシルラクチレート化合物を使用する皮膚透過増進剤組成物 |
JP2013514984A (ja) * | 2009-12-17 | 2013-05-02 | ザ・ポピュレイション・カウンシル,インコーポレイテッド | エストラジオール経皮ゲル剤(Nestorone(登録商標)) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5560922A (en) * | 1986-05-30 | 1996-10-01 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit using a polyacrylate adhesive polymer and process |
US5276022A (en) * | 1987-09-24 | 1994-01-04 | Jencap Research Ltd. | Hormone preparation and method |
US5256421A (en) * | 1987-09-24 | 1993-10-26 | Jencap Research Ltd. | Hormone preparation and method |
DE69125855T2 (de) * | 1990-06-01 | 1997-07-31 | The Population Council, New York, N.Y. | Therapeutisch wirksame, örtliche anwendung von st1435 |
US5320850A (en) * | 1990-10-29 | 1994-06-14 | Alza Corporation | Transdermal delivery of the gestogen ST-1435 and devices therefor |
JP2960832B2 (ja) * | 1992-05-08 | 1999-10-12 | ペルマテック テクノロジー アクチェンゲゼルシャフト | エストラジオールの投与システム |
US5900250A (en) * | 1992-05-13 | 1999-05-04 | Alza Corporation | Monoglyceride/lactate ester permeation enhancer for oxybutnin |
MX9303557A (es) * | 1992-08-06 | 1994-03-31 | Beta Pharm Co | Metodo para la administracion de un antiandrogeno, en particular, espironolactona, a traves de la piel. |
CA2114968A1 (en) * | 1993-02-25 | 1994-08-26 | John Wille | Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity |
EP0721348B1 (en) * | 1993-09-29 | 1999-09-01 | Alza Corporation | Monoglyceride/lactate ester permeation enhancer |
DE4400770C1 (de) * | 1994-01-13 | 1995-02-02 | Lohmann Therapie Syst Lts | Wirkstoffhaltiges Pflaster zur Abgabe von Estradiol mit mindestens einem Penetrationsverstärker, Verfahren zu seiner Herstellung und seine Verwendung |
DE19513662A1 (de) * | 1995-04-08 | 1996-10-10 | Schering Ag | Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption |
US5785991A (en) * | 1995-06-07 | 1998-07-28 | Alza Corporation | Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate |
AU726283B2 (en) * | 1995-06-28 | 2000-11-02 | Schering Aktiengesellschaft | Pharmaceutical combined preparations, kit and method for hormonal contraception |
DE19525017A1 (de) * | 1995-06-28 | 1997-01-02 | Schering Ag | Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption |
FR2739032B1 (fr) * | 1995-09-27 | 1997-11-21 | Lhd Lab Hygiene Dietetique | Systeme matriciel transdermique d'administration d'un oestrogene et/ou d'un progestatif a base d'eva, procede de preparation et utilisation en therapeutique |
US5730721A (en) * | 1996-01-25 | 1998-03-24 | Vesture Corporation | Medical applicator and method |
US6512010B1 (en) * | 1996-07-15 | 2003-01-28 | Alza Corporation | Formulations for the administration of fluoxetine |
US6203817B1 (en) | 1997-02-19 | 2001-03-20 | Alza Corporation | Reduction of skin reactions caused by transdermal drug delivery |
WO1999032153A1 (en) * | 1997-12-22 | 1999-07-01 | Alza Corporation | Monoglyceride and ethyl palmitate permeation enhancer compositions |
US6699497B1 (en) * | 1998-07-24 | 2004-03-02 | Alza Corporation | Formulations for the transdermal administration of fenoldopam |
PT1140039E (pt) | 1998-12-18 | 2010-02-03 | Alza Corp | Dispositivos transparentes de administração transdérmica de nicotina |
US7384650B2 (en) * | 1999-11-24 | 2008-06-10 | Agile Therapeutics, Inc. | Skin permeation enhancement composition for transdermal hormone delivery system |
US20080097149A1 (en) * | 2002-12-30 | 2008-04-24 | Sam Adler | Method for in Vivo Sensing |
US20040258742A1 (en) * | 2003-04-11 | 2004-12-23 | Van Osdol William Woodson | Transdermal administration of N-(2,5-disubstituted phenyl)-N'-(3-substituted phenyl)-N'-methyl guanidines |
US8518926B2 (en) * | 2006-04-10 | 2013-08-27 | Knopp Neurosciences, Inc. | Compositions and methods of using (R)-pramipexole |
WO2007121188A2 (en) * | 2006-04-10 | 2007-10-25 | Knopp Neurosciences, Inc. | Compositions and methods of using r(+) pramipexole |
AU2007253899A1 (en) * | 2006-05-16 | 2007-11-29 | Knopp Neurosciences, Inc. | Compositions of R(+) and S(-) pramipexole and methods of using the same |
US8524695B2 (en) * | 2006-12-14 | 2013-09-03 | Knopp Neurosciences, Inc. | Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same |
RU2454409C2 (ru) | 2007-03-14 | 2012-06-27 | Нопп Ньюросайенсиз, Инк. | Синтез хирально очищенных замещенных бензотиазолдиаминов |
JP5603235B2 (ja) * | 2007-07-10 | 2014-10-08 | アージャイル セラピューティクス, インコーポレイテッド | イン・サイチュシールを有する経皮送達デバイス |
US20100292660A1 (en) * | 2007-07-10 | 2010-11-18 | Agis Kydonieus | Dermal delivery device with ultrasonic weld |
CA2734491A1 (en) * | 2008-08-19 | 2010-02-25 | Knopp Neurosciences, Inc. | Compositions and methods of using (r)-pramipexole |
AU2010262970A1 (en) * | 2009-06-19 | 2012-01-12 | Knopp Neurosciences, Inc. | Compositions and methods for treating amyotrophic lateral sclerosis |
AU2012205791B2 (en) | 2011-01-10 | 2016-11-03 | Invion, Ltd. | Use of beta-adrenergic inverse agonists for smoking cessation |
WO2013096816A1 (en) | 2011-12-22 | 2013-06-27 | Biogen Idec Ma Inc. | Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds |
WO2013177570A1 (en) | 2012-05-25 | 2013-11-28 | Terapio Corporation | Methods of preventing or treating disease of the central nervous system using rlip76 |
US9662313B2 (en) | 2013-02-28 | 2017-05-30 | Knopp Biosciences Llc | Compositions and methods for treating amyotrophic lateral sclerosis in responders |
US9468630B2 (en) | 2013-07-12 | 2016-10-18 | Knopp Biosciences Llc | Compositions and methods for treating conditions related to increased eosinophils |
CN105764507B (zh) | 2013-07-12 | 2019-07-19 | 诺普生物科学有限责任公司 | 治疗升高的嗜酸性粒细胞和/或嗜碱性粒细胞的水平 |
ES2871556T3 (es) | 2013-08-13 | 2021-10-29 | Knopp Biosciences Llc | Composiciones y métodos para el tratamiento de la urticaria crónica |
AU2014306683B2 (en) | 2013-08-13 | 2017-10-12 | Knopp Biosciences Llc | Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders |
WO2015042163A1 (en) | 2013-09-17 | 2015-03-26 | Terapio Corporation | Methods of preventing or treating mucositis using rlip76 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3800038A (en) * | 1972-04-21 | 1974-03-26 | Biolog Concepts Inc | Uterine administraton of eutectic solid solutions of steroid hormones in a steroidal lipid carrier |
US4816258A (en) * | 1987-02-26 | 1989-03-28 | Alza Corporation | Transdermal contraceptive formulations |
CH674618A5 (ja) * | 1987-04-02 | 1990-06-29 | Ciba Geigy Ag |
-
1990
- 1990-10-29 US US07/605,726 patent/US5122382A/en not_active Expired - Lifetime
-
1991
- 1991-10-25 ZA ZA918531A patent/ZA918531B/xx unknown
- 1991-10-25 MX MX9101784A patent/MX9101784A/es unknown
- 1991-10-25 WO PCT/US1991/007877 patent/WO1992007589A1/en active IP Right Grant
- 1991-10-25 AU AU90419/91A patent/AU9041991A/en not_active Abandoned
- 1991-10-25 PT PT99340A patent/PT99340B/pt not_active IP Right Cessation
- 1991-10-25 NZ NZ240361A patent/NZ240361A/en not_active IP Right Cessation
- 1991-10-25 CA CA002088778A patent/CA2088778C/en not_active Expired - Lifetime
- 1991-10-25 EP EP92900228A patent/EP0577602B1/en not_active Expired - Lifetime
- 1991-10-25 ES ES92900228T patent/ES2123547T3/es not_active Expired - Lifetime
- 1991-10-25 IE IE374191A patent/IE913741A1/en not_active IP Right Cessation
- 1991-10-25 DE DE69130232T patent/DE69130232T2/de not_active Expired - Lifetime
- 1991-10-25 DK DK92900228T patent/DK0577602T3/da active
- 1991-10-25 AT AT92900228T patent/ATE171069T1/de not_active IP Right Cessation
- 1991-10-25 JP JP4500802A patent/JP2975684B2/ja not_active Expired - Lifetime
-
1993
- 1993-03-31 NO NO931209A patent/NO303527B1/no not_active IP Right Cessation
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11505843A (ja) * | 1995-05-26 | 1999-05-25 | アルザ コーポレイション | アシルラクチレート化合物を使用する皮膚透過増進剤組成物 |
JP2013514984A (ja) * | 2009-12-17 | 2013-05-02 | ザ・ポピュレイション・カウンシル,インコーポレイテッド | エストラジオール経皮ゲル剤(Nestorone(登録商標)) |
US9682087B2 (en) | 2009-12-17 | 2017-06-20 | The Population Council, Inc. | Nestorone®/estradiol transdermal gel |
Also Published As
Publication number | Publication date |
---|---|
CA2088778C (en) | 2001-08-14 |
IE913741A1 (en) | 1992-05-22 |
ES2123547T3 (es) | 1999-01-16 |
DK0577602T3 (da) | 1999-06-14 |
WO1992007589A1 (en) | 1992-05-14 |
EP0577602A1 (en) | 1994-01-12 |
JP2975684B2 (ja) | 1999-11-10 |
NO931209D0 (no) | 1993-03-31 |
ATE171069T1 (de) | 1998-10-15 |
EP0577602B1 (en) | 1998-09-16 |
PT99340B (pt) | 1999-02-26 |
CA2088778A1 (en) | 1992-04-30 |
NO931209L (no) | 1993-04-26 |
NO303527B1 (no) | 1998-07-27 |
AU9041991A (en) | 1992-05-26 |
NZ240361A (en) | 1995-07-26 |
MX9101784A (es) | 1992-06-05 |
DE69130232D1 (de) | 1998-10-22 |
DE69130232T2 (de) | 1999-04-08 |
ZA918531B (en) | 1992-08-26 |
PT99340A (pt) | 1992-09-30 |
US5122382A (en) | 1992-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH06502429A (ja) | 経皮避妊製剤、方法及びデバイス | |
US5686097A (en) | Monoglyceride/lactate ester permeation enhancer for codelivery of steroids | |
AU657502B2 (en) | Transdermal contraceptive formulations, methods and devices | |
US5314694A (en) | Transdermal formulations, methods and devices | |
JP3786684B2 (ja) | オキシブチニンの経皮投与 | |
US5198223A (en) | Transdermal formulations, methods and devices | |
US5422119A (en) | Transdermal hormone replacement therapy | |
JP3068187B2 (ja) | 促進された薬物流量を提供する準飽和の経皮薬物送達装置 | |
US5512292A (en) | Transdermal contraceptive formulations methods and devices | |
US4910205A (en) | Transdermal delivery of loratadine | |
JP2014051507A (ja) | 避妊及びホルモン補充のためのノルエルゲストロミンを含む経皮治療システム | |
JP2010500992A (ja) | アルツハイマー病の経皮的治療法及び経皮的治療システム | |
JPH04505157A (ja) | 皮膚透過性促進組成物 | |
JPH04504109A (ja) | エストロゲン/プロゲスチン経皮投与ユニット,そのシステムとプロセス | |
JPH02500740A (ja) | 経皮的生殖能調節システムおよび方法 | |
CZ240297A3 (cs) | Transdermální přípravek | |
US5320850A (en) | Transdermal delivery of the gestogen ST-1435 and devices therefor | |
CA2152780A1 (en) | Transdermal hormone replacement therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20070903 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080903 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080903 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090903 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090903 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100903 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110903 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110903 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120903 Year of fee payment: 13 |
|
EXPY | Cancellation because of completion of term | ||
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120903 Year of fee payment: 13 |